CRISPR Therapeutics AG — Director's Dealing 2017

Nov 14, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2017-11-13

Reporting Person: TOMSICEK MICHAEL JOHN (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-13	Stock Option (Right to Buy)	$17.75	A	180000	Acquired	2027-11-21	Common Shares (180000)	Direct

Footnotes

F1: This option was granted on November 13, 2017, 25% of the shares shall vest on November 13, 2018 and the remaining shares shall vest in 36 equal monthly installments on the first day of each succeeding calendar month.